Icecure Medical is trading at $1.38, down 10.39%, during the October 6 session; no clear same-day company-specific cause was identified.

  • Legacy Health joined its FDA-approved ChoICE post-market study, expected to enroll about 400 patients across up to 30 U.S. sites; the positive update does not explain the decline.
  • U.S. stocks were higher, so broad market strength does not account for the move.